OcuSciences was formed to develop a technology that can rapidly and non-invasively detect and monitor retinal metabolic dysfunction at an earlier stage than currently possible.

Our Mission

OcuSciences plans to establish RMA as a standard tool for detecting and monitoring retinal metabolic dysfunction in primary eye care practices throughout the world. Our mission is to assist in the early detection of diabetes and pre-diabetes and the monitoring of disease progression due to retinal cell damage.  Currently, most adults do not get screened regularly for diabetes due to the cumbersome nature of existing screening methods, as they are invasive, require fasting and involve blood draws. Thus, there are 8.1 million undiagnosed diabetics in the US (29.1 million total) and 79 million pre-diabetics. As most adults visit a primary eye care practice for reading glasses starting at the age of 40, primary eye care is a perfect initial venue for screening for diabetes and monitoring disease progression.

Company Overview

OcuSciences, Inc., is a medical diagnostic device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible.

Currently, OcuSciences is developing a medical device technology, the OcuMet Beacon, that can provide a high quality fundus, back of the eye, photograph and using the RMA technology, provide a metabolic signature of the health of retinal cells. We are currently focused on developing the technology to investigate the ocular manifestations of diabetes and therapies aimed at treating them. At the earliest stages of diabetic eye disease, before clinically visible complications are present, there is increased oxidative stress and mitochondrial dysfunction present in the retinal cells. We are developing RMA to detect mitochondrial dysfunction in a number of retinal diseases, including in diabetics with and without retinopathy, with the latter having even more mitochondrial dysfunction. Thus, RMA is being designed as the first non-invasive, rapid, easy-to-use, and affordable tool to detect early retinal disease, including the earliest retinal complications of diabetes.